A harmonised framework on one side, a single federal regulator on the other.
EMA coordinates the centralised procedure, while national competent authorities handle national, decentralised and mutual-recognition routes. Biotechnology-derived biosimilars require the centralised route. National access and distribution requirements also shape planning.
Kaiveo Medical helps Chinese pharmaceutical companies assess dossier readiness, manufacturing compliance, clinical evidence and market sequencing through founder-led coordination. For drug-led combination products, the medicines pathway leads, with device-component requirements assessed as applicable. Import, testing and statutory-role needs are assessed with your responsible functions.
Challenges we solve
Centralised versus decentralised or national, and in which order to approach member states.
CTD gap closure, Module 3 depth, bioequivalence and clinical-overview quality that European assessors expect.
Inspection readiness for API and finished-product sites, data-integrity programmes and CDMO oversight.
Assessment of import, testing and QP requirements, with appropriately qualified providers identified as needed; appointments agreed separately.
Comparability exercise design, reference-product sourcing and European biosimilar guideline alignment.
Variations, renewals and regulatory intelligence within scope; safety-system and QPPV needs assessed with your responsible functions.
How we support pharma clients
Regulatory Affairs
MAA strategy, agency dialogue and dossier delivery.
Clinical Research Management
Global study design, start-up coordination and oversight planning.
Quality & Compliance
EU GMP readiness, supplier audits and remediation.
Clinical & Medical Affairs
Medical evidence and scientific engagement planning.
The same product, two regulators
Approval in one market does not carry over to the other. The relevance and sufficiency of existing evidence must be assessed for each intended route.
In Europe
- EMA centralised or NCA national, decentralised / MRP routes
- EU GMP readiness and assessment of QP batch-release needs
- Assessment of safety and trial legal-representation requirements
- Importation and supply-chain requirements assessment
- Orphan designation, PRIME eligibility and paediatric plans
- Early HTA and payer evidence questions
In the United States
- IND for clinical trials; NDA 505(b)(1)/(2) or ANDA for generics
- BLA 351(a) for biologics or 351(k) for biosimilars
- cGMP under 21 CFR Parts 210 and 211, and FDA inspection
- Fast Track, Breakthrough Therapy and Priority Review
- Assessment of US payer evidence questions
A typical pharma pathway
Product, data and manufacturing assessed; European procedure and market sequence recommended.
CTD gaps closed while manufacturing sites are brought to EU GMP inspection readiness in parallel.
Agreed submission coordination and support for questions and inspections; regulatory decisions remain with the authorities.
Agreed lifecycle planning and coordination of launch requirements with your appointed responsible functions and providers.
